In contrast, IRX1 was linked with preserved 30-year brain volumes (GMF, MEDW and TVW), reduced risk of cortical lesions, lower 30-year EDSS and in MS patients, lower risk of SPMS and slower EDSS worsening. Here, IRX1 is linked to secondary progressive multiple sclerosis.